A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: The Italian experience

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 1, 2004, Pages 217-220

  Cascio, Antonio ^a,b   di Martino, Lucio ^c   Occorsio, Paolo ^c   Giacchino, Raffaella ^d   Catania, Salvatore ^e   Gigliotti, Anna Rita ^d   Aiassa, Camilla ^e   Iaria, Chiara ^a,b   Giordano, Salvatore ^f   Colomba, Claudia ^f   Polara, Valentina Frasca ^f   Titone, Lucina ^f   Gradoni, Luigi ^g   Gramiccia, Marina ^g   Antinori, Spinello ^h  

^a UNIVERSITY OF MESSINA   (Italy)

^b AILMI ONLUS   (Italy)

^c SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

^g ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

Italy; Leishmania infantum; Therapy

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; MEGLUMINE ANTIMONATE;

ADOLESCENT; ARTICLE; CHILD; CHILD HEALTH CARE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFANT DISEASE; ITALY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; PATIENT REFERRAL; PEDIATRIC HOSPITAL; RELAPSE; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; VALIDATION PROCESS; VISCERAL LEISHMANIASIS;

ADOLESCENT; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; BONE MARROW; CHILD; CHILD, PRESCHOOL; DRUG CARRIERS; FEMALE; FEVER; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INFANT; ITALY; LEISHMANIASIS, VISCERAL; LIPOSOMES; MALE; NUTRITIONAL STATUS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 3543062878     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh279     Document Type: Article

References (19)

1. Desjeux, P. (2001). The increase in risk factors for leishmaniasis worldwide. Transactions of the Royal Society of Tropical Medicine and Hygiene 95, 239-43.
2. Di Cristina, G. & Caronia, G. (1915). Sulla terapia della leishmaniosi interna. Pathologica 7, 82-3.
3. Murray, H. W. (2000). Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. International Journal of Infectious Diseases 4, 158-77.
4. Cascio, A., Gradoni, L., Scarlata, F. et al. (1997). Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy. American Journal of Tropical Medicine and Hygiene 57, 75-8.
5. Cascio, A., Colomba, C., Antinori, S. et al. (2002). Pediatric visceral leishmaniasis in Western Sicily Italy: a retrospective analysis of 111 cases. European Journal of Clinical Microbiology & Infectious Diseases 21, 277-82.
6. Meyerhoff, A. (1999). U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clinical Infectious Diseases 28, 42-8.
7. di Martino, L., Davidson, R. N., Giacchino, R. et al. (1997). Treatment of visceral leishmaniasis in children with liposomal amphotericin-B. Journal of Pediatrics 131, 271-7.
8. Gramiccia, M., Gradoni, L. & Angelici, M. C. (1989). Epidemiology of Mediterranean leishmaniasis caused by Leishmania infantum: isoenzyme and kDNA analysis for the identification of parasites from man, vectors and reservoirs. In Leishmaniasis. The Current Status and New Strategies for Control. (Hart, D. T., Ed.), NATO ASI Series, Series A Volume 163, pp. 21-37. Plenum Publishing Corporation, New York, USA.
9. Davidson, R. N., di Martino, L., Gradoni, L. et al. (1996). Short course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clinical Infectious Diseases 22, 938-43.
10. Davidson, R. N., di Martino, L., Gradoni, L. et al. (1994). Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multicentre trial. Quarterly Journal of Medicine 87, 75-81.
11. Gramiccia, M., Gradoni, L., di Martino, L. et al. (1992). Two syntopic zymodemes of Leishmania infantum cause human and canine visceral leishmaniasis in the Naples area, Italy. Acta Tropica 50, 357-9.
12. Lira, R., Sundre, S., Makharia, A. et al. (1988). Evidence that the high incidence of treatment failure in Indian Kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. Journal of Infectious Diseases 180, 564-7.
13. Sundar, S. (2001). Drug resistance in Indian visceral leishmaniasis. Tropical Medicine and International Health 6, 849-854.
14. Gradoni, L., Gramiccia, M. & Scalone, A. (2003). Visceral leishmaniasis treatment Italy. Emerging Infectious Diseases 9, 1617-20.
15. Pagliano, P., Rossi, M., Rescigno, C. et al. (2003). Mediterranean visceral leishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995-2001). Journal of Antimicrobial Chemotherapy 52, 264-8.
16. Syriopoulou, V., Daikos, G. L., Theodoridou, M. et al. (2003). Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clinical Infectious Diseases 36, 560-6.
17. Sundar, S., Agrawal, G., Rai, M. et al. (2001). Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. British Medical Journal 323, 419-22.
18. Vanderbos, F., Marty, P., Rosenthal, E. et al. (2003). Single injection of liposomal amphotericin B (AmBisome) in sub-acute Mediterranean visceral leishmaniasis. British Medical Journal 326, 377.
19. Berman, J. D., Badaro, R., Thakur, C. P. et al. (1998). Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bulletin of the World Health Organization 76, 25-32.